157 related articles for article (PubMed ID: 8774570)
21. Progressive glomerular toxicity of ifosfamide in children.
Prasad VK; Lewis IJ; Aparicio SR; Heney D; Hale JP; Bailey CC; Kinsey SE
Med Pediatr Oncol; 1996 Sep; 27(3):149-55. PubMed ID: 8699991
[TBL] [Abstract][Full Text] [Related]
22. Progressive renal toxicity due to ifosfamide.
Heney D; Wheeldon J; Rushworth P; Chapman C; Lewis IJ; Bailey CC
Arch Dis Child; 1991 Aug; 66(8):966-70. PubMed ID: 1718222
[TBL] [Abstract][Full Text] [Related]
23. [Ifosphamide nephrotoxicity].
Ensergueix G; Karras A
Nephrol Ther; 2018 Apr; 14 Suppl 1():S125-S131. PubMed ID: 29606257
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for cisplatin-induced long-term nephrotoxicity in pediatric cancer survivors.
Arga M; Oguz A; Pinarli FG; Karadeniz C; Citak EC; Emeksiz HC; Duran EA; Soylemezoglu O
Pediatr Int; 2015 Jun; 57(3):406-13. PubMed ID: 25441241
[TBL] [Abstract][Full Text] [Related]
25. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma.
Koch Nogueira PC; Hadj-Aïssa A; Schell M; Dubourg L; Brunat-Mentigny M; Cochat P
Pediatr Nephrol; 1998 Sep; 12(7):572-5. PubMed ID: 9761357
[TBL] [Abstract][Full Text] [Related]
26. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
Raney B; Ensign LG; Foreman J; Khan F; Newton W; Ortega J; Ragab A; Wharam M; Wiener E; Maurer H
Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):286-95. PubMed ID: 7978043
[TBL] [Abstract][Full Text] [Related]
27. Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
Oberlin O; Fawaz O; Rey A; Niaudet P; Ridola V; Orbach D; Bergeron C; Defachelles AS; Gentet JC; Schmitt C; Rubie H; Munzer M; Plantaz D; Deville A; Minard V; Corradini N; Leverger G; de Vathaire F
J Clin Oncol; 2009 Nov; 27(32):5350-5. PubMed ID: 19826134
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin dose rate as a risk factor for nephrotoxicity in children.
Skinner R; Pearson AD; English MW; Price L; Wyllie RA; Coulthard MG; Craft AW
Br J Cancer; 1998 May; 77(10):1677-82. PubMed ID: 9635848
[TBL] [Abstract][Full Text] [Related]
29. Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.
Suarez A; McDowell H; Niaudet P; Comoy E; Flamant F
J Clin Oncol; 1991 Dec; 9(12):2177-82. PubMed ID: 1720453
[TBL] [Abstract][Full Text] [Related]
30. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.
Goren MP; Wright RK; Pratt CB; Horowitz ME; Dodge RK; Viar MJ; Kovnar EH
Cancer Res; 1987 Mar; 47(5):1457-60. PubMed ID: 3815347
[TBL] [Abstract][Full Text] [Related]
31. Renal toxicity of cancer chemotherapeutic agents in children: ifosfamide and cisplatin.
Jones DP; Chesney RW
Curr Opin Pediatr; 1995 Apr; 7(2):208-13. PubMed ID: 7787938
[TBL] [Abstract][Full Text] [Related]
32. Tubular nephrotoxicity during long-term ifosfamide and mesna therapy.
Goren MP; Pratt CB; Viar MJ
Cancer Chemother Pharmacol; 1989; 25(1):70-2. PubMed ID: 2574077
[TBL] [Abstract][Full Text] [Related]
33. Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna.
Goren MP; Wright RK; Horowitz ME; Pratt CB
Cancer Treat Rep; 1987 Feb; 71(2):127-30. PubMed ID: 2879626
[TBL] [Abstract][Full Text] [Related]
34. The influence of age on nephrotoxicity following chemotherapy in children.
Skinner R; Pearson AD; Price L; Coulthard MG; Craft AW
Br J Cancer Suppl; 1992 Aug; 18():S30-5. PubMed ID: 1503924
[TBL] [Abstract][Full Text] [Related]
35. Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor.
Burk CD; Restaino I; Kaplan BS; Meadows AT
J Pediatr; 1990 Aug; 117(2 Pt 1):331-5. PubMed ID: 2166154
[TBL] [Abstract][Full Text] [Related]
36. [Ifosfamide-induced nephrotoxicity].
Rossi R; Rath B; Ullrich K; Ehrich JH
Monatsschr Kinderheilkd; 1993 Jul; 141(7):594-601. PubMed ID: 8413339
[TBL] [Abstract][Full Text] [Related]
37. Renal function abnormalities after ifosfamide treatment in children.
De Schepper J; Hachimi-Idrissi S; Verboven M; Piepsz A; Otten J
Acta Paediatr; 1993 Apr; 82(4):373-6. PubMed ID: 8318805
[TBL] [Abstract][Full Text] [Related]
38. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
39. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Antman KH; Elias A; Ryan L
Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
[TBL] [Abstract][Full Text] [Related]
40. Ifosfamide-induced subclinical nephrotoxicity and its potentiation by cisplatinum.
Rossi R; Danzebrink S; Hillebrand D; Linnenbürger K; Ullrich K; Jürgens H
Med Pediatr Oncol; 1994; 22(1):27-32. PubMed ID: 8232077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
